| Market Capitalization (Millions $) |
15 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
13 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-22 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
BioVie Inc. is a clinical-stage biotechnology company focused on developing drugs that can be used to treat chronic liver diseases like cirrhosis. They are currently developing a medication called BIV201, which has the potential to treat Ascites or abdominal fluid buildup, which is a life-threatening complication of liver cirrhosis.
The company was founded in 2013 and has its headquarters in Beverly Hills, California. They are publicly traded on the NASDAQ stock exchange under the ticker symbol BIVI.
One of the key strengths of BioVie is its management team. The company is led by experienced medical and business leaders who have a proven track record in the biotechnology industry. This has enabled BioVie to attract partnerships and funding from leading organizations like the National Institutes of Health (NIH).
BioVie's primary drug candidate, BIV201, is a proprietary formulation that combines two existing drugs. One of these drugs is Terlipressin, which is used in Europe to treat Ascites but is not available in the United States. The other drug is a vasopressin receptor antagonist, which helps to reduce the side effects of Terlipressin. By combining these two drugs, BioVie hopes to create a medication that is both effective and safe.
The company has completed several early-stage clinical trials of BIV201, which have shown promising results. In one study, patients who received BIV201 had a 58% reduction in Ascites compared to those who received a placebo.
BioVie is also exploring other potential uses for BIV201, such as the treatment of other types of liver disease and certain types of cancer. They are also developing other drug candidates that can be used to treat liver disease and other medical conditions.
In conclusion, BioVie Inc is a clinical-stage biotechnology company that is focused on developing innovative drugs to treat chronic liver diseases. Their primary drug candidate, BIV201, has shown promising results in early-stage clinical trials and has the potential to treat a life-threatening complication of cirrhosis. With an experienced management team and partnerships with leading organizations, BioVie has the potential to become a significant player in the biotechnology industry.
Company Address: 680 W Nye Lane Suite 201 Carson City 89703 NV
Company Phone Number: 888-3162 Stock Exchange / Ticker: NASDAQ BIVI
|
1.92% 